DSM Capital Partners LLC Makes New $307,000 Investment in Boston Scientific Corporation $BSX

Key Points

• DSM Capital Partners LLC invested approximately $307,000 in Boston Scientific Corporation, acquiring 2,858 shares during the second quarter.
• Boston Scientific reported earnings of $0.75 per share for the quarter, exceeding analysts' estimates of $0.72, with revenue rising 22.8% year-over-year to $5.06 billion.
• Shares of Boston Scientific are currently trading 1.9% lower, with a market cap of $141.38 billion and a consensus rating of "Buy" among analysts.

DSM Capital Partners LLC purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,858 shares of the medical equipment provider's stock, valued at approximately $307,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BSX. Brighton Jones LLC lifted its position in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after buying an additional 226 shares in the last quarter. Farther Finance Advisors LLC lifted its position in Boston Scientific by 9.1% during the 1st quarter. Farther Finance Advisors LLC now owns 12,062 shares of the medical equipment provider's stock worth $1,221,000 after buying an additional 1,002 shares in the last quarter. Wealthcare Advisory Partners LLC lifted its position in Boston Scientific by 25.8% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 3,675 shares of the medical equipment provider's stock worth $371,000 after buying an additional 754 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Boston Scientific by 17.2% during the 1st quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider's stock worth $2,578,000 after purchasing an additional 3,745 shares during the last quarter. Finally, Integrated Advisors Network LLC raised its holdings in shares of Boston Scientific by 4.5% in the 1st quarter. Integrated Advisors Network LLC now owns 6,836 shares of the medical equipment provider's stock valued at $690,000 after purchasing an additional 296 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Down 1.9%

Shares of BSX opened at $95.41 on Friday. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The firm has a market cap of $141.38 billion, a P/E ratio of 56.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. The firm's 50-day simple moving average is $101.98 and its 200 day simple moving average is $101.87. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the business posted $0.62 EPS. The business's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BSX shares. Robert W. Baird upped their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the company an "outperform" rating in a report on Wednesday, October 1st. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $125.00 target price on shares of Boston Scientific in a report on Monday, September 29th. Needham & Company LLC reaffirmed a "buy" rating and issued a $121.00 target price on shares of Boston Scientific in a report on Wednesday, October 1st. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Evercore ISI dropped their target price on shares of Boston Scientific from $115.00 to $110.00 and set an "outperform" rating on the stock in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $120.71.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.